Patents Assigned to VGX PHARMACEUTICALS, LLC
  • Publication number: 20190167983
    Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 6, 2019
    Applicant: VGX Pharmaceuticals, LLC
    Inventors: Thomas Joseph KARDOS, Stephen Vincent KEMMERRER, Rune KJEKEN, Kate BRODERICK, Jay MCCOY, Michael P. FONS
  • Patent number: 10232173
    Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: March 19, 2019
    Assignee: VGX Pharmaceuticals, LLC
    Inventors: Thomas Joseph Kardos, Stephen Vincent Kemmerer, Rune Kjeken, Kate Broderick, Jay McCoy, Michael P Fons
  • Patent number: 8961994
    Abstract: Aspects of the present invention relate to isolated nucleic acids that encode a consensus DIII domain of protein E and vaccines made using same, and also methods for using the aforementioned to generate in a host an immune response against multiple serotypes of flavivirus, particularly West Nile virus and Japanese encephalitis virus.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: February 24, 2015
    Assignee: VGX Pharmaceuticals, LLC
    Inventors: Mathura P. Ramanathan, Niranjan Y Sardesai
  • Patent number: 8835620
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: September 16, 2014
    Assignee: VGX Pharmaceuticals, LLC
    Inventors: Mathura P. Ramanathan, Niranjan Sardesai
  • Publication number: 20120046598
    Abstract: Devices and methods for delivering an electropermeabilizing pulse of electric energy to a tissue surface to enable delivery into cells in the tissue therapeutic substances. The device incorporates a source capable of generating a sufficient voltage potential to deliver a spark across a gap and delivers same to the tissue surface.
    Type: Application
    Filed: April 16, 2010
    Publication date: February 23, 2012
    Applicant: VGX PHARMACEUTICALS, LLC
    Inventors: Thomas Joseph Kardos, Stephen Vincent Kemmerer, Rune Kjeken, Kate Broderick, Jay McCoy, Michael P Fons
  • Publication number: 20110070640
    Abstract: One aspect of the current invention is an optimized synthetic mammalian expression plasmid with a mutated origin of replication (e.g. “mut” family of plasmids) comprising a therapeutic element, and a replication element. The therapeutic elements of this plasmid are operatively linked and located in a first operatively-linked arrangement. Additionally, the optimized synthetic mammalian expression plasmid comprises replication elements, wherein the replication elements are operatively linked and located in a second operatively-linked arrangement. The first-operatively-linked arrangement and the second-operatively-linked arrangement comprise a circular structure of the codon optimized synthetic mammalian expression plasmid.
    Type: Application
    Filed: November 17, 2010
    Publication date: March 24, 2011
    Applicant: VGX PHARMACEUTICALS, LLC
    Inventors: Ruxandra DRAGHIA-AKLI, Melissa POPE
  • Publication number: 20110034544
    Abstract: Compositions and kits comprising a nucleotide sequence that encodes GHRH and a nucleotide sequence that encodes GnRH and compositions and kits comprising a GHRH protein and GnRH protein are disclosed. Use of such compositions and kits in methods of enhancing fertility in mammals comprising the step of administering said compositions to the mammal are disclosed.
    Type: Application
    Filed: March 6, 2009
    Publication date: February 10, 2011
    Applicant: VGX PHARMACEUTICALS, LLC
    Inventors: Ruxandra Draghia-Akli, Amir Khan, Patricia Brown
  • Publication number: 20100291144
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal.
    Type: Application
    Filed: January 12, 2009
    Publication date: November 18, 2010
    Applicant: VGX PHARMACEUTICALS, LLC
    Inventors: Mathura P Ramanathan, Niranjan Y Sardesai
  • Publication number: 20100247437
    Abstract: The present invention is directed towards materials and methods of delivering biomolecules to cells that define an organ, and the organ being in situ, and electroporating cells defining the organ by delivering to the cells an amount of energy effective to electroporate the cells. The present invention is also directed towards materials and methods of expressing heterologous polypeptides in organs of a subject and electroporating cells defining the organ by delivering to the cells an amount of energy effective to electroporate the cells.
    Type: Application
    Filed: September 24, 2008
    Publication date: September 30, 2010
    Applicant: VGX PHARMACEUTICALS, LLC
    Inventor: Ruxandra Draghia-Akli